Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Crescita Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®
Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...
Product Name : Pliaglis
Product Type : Other Small Molecule
Upfront Cash : $0.7 million
December 13, 2021
Lead Product(s) : Lidocaine,Tetracaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Crescita Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : National Institute of Pharmacy and Nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
Egis Favipiravir Drug Licenced for Covid-19 Treatment
Details : The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).
Product Name : Favipiravir-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : National Institute of Pharmacy and Nutrition
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY PRODUCTS
Reset All
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
